Orforglipron for adults who are overweight and at risk of obesity-related health problems
Tests orforglipron against placebo in adults who are overweight.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Key facts
- Where
- A coruña, Alcobendas, Barcelona, Centelles, Chiclana De La Frontera, Granada, Madrid, Sevilla, and Valencia, SpainSee the 13 sites
- Phase
- Phase 3
Where in Spain
- C.R.A. Investigación ClínicaA coruña, SpainTaking people
- Accellacare Espana S.L.Alcobendas, SpainTaking people
- Equip D'atencio Primaria Barcelona Sardenya S.L.P.Barcelona, SpainTaking people
- FutureMeds BarcelonaBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- EAP Osona Sud - Alt Congost S.L.PCentelles, SpainTaking people
- Futuremeds Spain S.L.Chiclana De La Frontera, SpainTaking people
- Hospital Vithas La SaludGranada, SpainTaking people
- Centro de Salud San Juan de la CruzMadrid, SpainTaking people
- Futuremeds Spain S.L.Madrid, SpainTaking people
- Futuremeds Spain S.L.Sevilla, SpainTaking people
- Vithas Hospital SevillaSevilla, SpainTaking people
- Hospital AsciresValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07794579EU 2026-526175-35-00
- Record updated
- 5 November 2026
- Original description
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.Read full original descriptionShow less
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Inclusion: Have an increased waist-to-height ratio of ≥0.5; Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia); Have at least one unsuccessful attempt to reduce body weight based on diet and exercise; Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds.
Exclusion: Do not have a stable body weight within 90 days before screening; Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening; Have a prior or planned surgical treatment or procedure for obesity; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold); Have hypertension or history of hypertension; Have dyslipidemia or history of dyslipidemia.